JP MORGAN/CALL/VERTEX PHARMACEUTICALS/415/0.1/19.07.24

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/415/0.1/19.07.24 Share Price

Warrant

DE000JB8G967

Market Closed - Börse Stuttgart 01:29:39 20/06/2024 pm IST
5.22 ^EUR	+3.16%

1 month	+35.58%
3 months	+64.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/415/0.1/19.07.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex to Announce Second Quarter 2024 Financial Results on August 1	02/07	BU
Verve Therapeutics, Inc. Announces Board Appointments	28/06	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	27/06	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	25/06	MT

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JB8G96
ISIN	DE000JB8G967
Date issued	04/12/2023
Strike	415 $
Maturity	19/07/2024 (18 Days)
Parity	10 : 1
Emission price	1.31 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	6.88 €
Lowest since issue	1.46 €

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company